Levosalbutamol, Ambroxol & Guaiphenesin

This oral liquid formulation belongs to the Syrups segment of the respiratory medicines category. It is a highly synergistic combination of a selective bronchodilator (Levosalbutamol), a potent mucolytic (Ambroxol), and an expectorant (Guaiphenesin, formally known as Guaifenesin under international nomenclature).

Unlike single-action cough suppressants that trap mucus in the lungs, this triple-combination is actively pro-clearance. It opens constricted airways, breaks down thick mucus, and stimulates the respiratory tract to expel the phlegm. This comprehensive mechanism makes it a first-line prescription choice for managing asthma, bronchitis, and COPD exacerbations accompanied by productive (chesty) coughs.

For pharmaceutical marketing companies and B2B distributors, this formulation represents one of the highest-velocity products in the Indian respiratory market. Brands built on this combination see massive seasonal spikes during winter and monsoon months. Saar Biotech’s dedicated liquid manufacturing facility in Baddi produces this syrup to exacting Indian Pharmacopoeia (IP) standards, ensuring your brand delivers the clinical efficacy that pediatricians, pulmonologists, and general physicians trust.

Formulating a stable, clinically effective liquid containing three distinct active pharmaceutical ingredients is technically demanding. The APIs must remain perfectly solubilized without interacting, and the extreme bitterness of the raw molecules must be neutralized to ensure patient compliance. As a leading expectorant syrup manufacturer Baddi, we have perfected this multi-API matrix.

• High-Shear Homogenization: We utilize advanced, temperature-controlled mixing vessels to ensure all three active molecules are permanently and uniformly dispersed within the syrupy base. This guarantees precise dose-to-dose consistency from the first pour to the last.
• Advanced Taste-Masking: Both Ambroxol and Guaifenesin possess a harsh, bitter profile. Our formulation team expertly neutralizes these notes using premium cooling flavors (such as Mint or Mixed Fruit), delivering a highly palatable syrup that maximizes compliance in both adult and pediatric populations.
• Optimized Viscosity: The syrup is engineered to be thick enough to provide a soothing, demulcent coating to the irritated pharynx (throat) as it is swallowed, yet fluid enough to pour cleanly into a measuring cup without crystallizing around the bottle cap.
• pH-Buffered Vehicle: The liquid matrix is formulated within a strictly controlled pH range to prevent the hydrolytic degradation of Levosalbutamol over the product’s 24-month shelf life, ensuring 100% label claim potency.

Manufactured and supplied from our third-party manufacturing facility in Himachal Pradesh, this syrup is formulated to target the following DCGI-approved clinical indications:

• Productive Cough with Bronchospasm: The primary indication. Relieves chesty coughs where thick mucus is accompanied by wheezing and airway constriction.
• Bronchial Asthma: Used in the management of acute asthmatic episodes to dilate the airways while preventing mucus plugging.
• Chronic Obstructive Pulmonary Disease (COPD): Highly effective in managing the chronic, thick sputum production and poor airflow associated with COPD and emphysema.
• Acute & Chronic Bronchitis: Breaks the cycle of intense coughing and chest tightness by thinning airway secretions and accelerating mucociliary clearance.

This formulation requires careful dosage adherence and is widely prescribed across pediatric and adult respiratory settings.

Clinical Mechanism

This formulation works through an elegant, three-pronged pharmacological approach:

1. Levosalbutamol (Bronchodilator): The pure R-enantiomer of salbutamol. It selectively binds to beta-2 adrenergic receptors in the bronchial smooth muscle, stimulating intracellular adenyl cyclase. This increases cAMP levels, leading to smooth muscle relaxation and immediate bronchodilation, opening the airways with minimal cardiac side effects.
2. Ambroxol Hydrochloride (Mucolytic): A metabolite of bromhexine. It depolymerizes (breaks down) the acid mucopolysaccharide fibers in the sputum. This drastically reduces the viscosity (thickness) of the mucus, making it watery and easy to mobilize.
3. Guaiphenesin / Guaifenesin (Expectorant): It stimulates the gastric vagal receptors, which triggers an efferent parasympathetic reflex that increases the volume of glandular secretions in the respiratory tract. This increased fluid volume further thins the mucus and lubricates the irritated airway.

Manufacturing Integrity

• Multi-API Stability: The combination of a beta-agonist, a mucolytic, and an expectorant in an aqueous base presents a high risk of cross-interaction. Our compounding protocols utilize specific sequential addition and pH buffering to isolate the molecules, preventing degradation and ensuring all three APIs remain chemically inert to one another.
• Prevention of Sugar Crystallization: To maintain the smooth texture of the syrup and prevent “cap-locking” (where sugar crystallizes and seals the bottle shut), we utilize a precise ratio of sucrose to non-crystallizing sorbitol/glycerin bases, ensuring a perfect pour every time.

For pharmaceutical marketers, the commercial value of this suspension lies in its rapid bioperformance and safety profile:

• Rapid Systemic Absorption: All three active ingredients are rapidly and completely absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations (Cmax) are typically achieved within 1 to 2.5 hours, providing rapid symptomatic relief for patients suffering from acute coughing fits.
• The Levosalbutamol Advantage: By utilizing Levosalbutamol instead of racemic Salbutamol, the required therapeutic dose is cut in half (1mg instead of 2mg). This drastically reduces the systemic beta-mediated side effects (like hand tremors and heart palpitations), giving your brand a distinct safety advantage that pediatricians heavily prefer.
• Synergistic Clearance: While Levosalbutamol physically widens the airway, Ambroxol and Guaifenesin reduce mucus viscosity. This synergistic action means the patient expends significantly less energy to clear the lungs, accelerating recovery time.
• Optimized Pack Sizes: The availability of 60ml, 100ml, and 120ml configurations allows prescribers to perfectly match the volume to the duration of the patient’s illness, minimizing wastage for pediatric cases and providing sufficient volume for chronic adult COPD therapy.

Saar Biotech offers comprehensive Contract Manufacturing Cough Syrups services from our high-capacity liquid manufacturing block. If you are seeking a reliable Respiratory contract manufacturing India partner, our Baddi facility provides:

• Facility: Segregated, contamination-controlled liquid manufacturing block with fully automated, high-speed filling, capping, and labeling lines.
• Capacity: Scalable from introductory 10,000-unit private-label launches to massive commercial deployments exceeding 2,00,000+ units per batch.
• Quality Lab: In-house GLP-certified analytical laboratories equipped with calibrated viscometers, pH meters, and Agilent HPLC systems for precise multi-API assaying.
• Turnaround: 30–45 working days for new manufacturing agreements; 20–25 working days for established partners on repeat orders—crucial for managing sudden winter demand surges.
• Packaging: Pharmaceutical-grade 60ml, 100ml, and 120ml amber PET bottles, precision measuring cups, and bespoke gloss or matte-finish mono-cartons.
• Regulatory: Full Schedule M and DCGI compliance, and complete Batch Manufacturing Record (BMR) transparency for rapid Indian market entry.
• MOQ: 5,000–10,000 units per SKU, structured to support both new-brand market entry and large-scale pan-India supply.

1. Warehousing Conditions: Store sealed cartons in a cool, dry environment strictly below 30°C. Elevated ambient temperatures can alter the viscosity of the syrupy base and accelerate API degradation.
2. Light Protection: Direct sunlight exposure degrades the flavoring system and can affect the stability of Levosalbutamol. Amber PET bottles and opaque mono-carton packaging provide essential photo-protection during transit and retail display.
3. Freeze Protection: This syrup must not be exposed to sub-zero temperatures. Freezing can cause the sugars to permanently crystallize and alter the uniform distribution of the APIs.
4. End-User Instruction: Patients should be advised to close the cap tightly immediately after use to prevent contamination and moisture ingress, and to use the provided measuring cup for accurate dosing.

As a leading Levosalbutamol Ambroxol WHO-GMP manufacturer India, every batch released from our facility undergoes an exhaustive analytical testing battery:

• Multiplex HPLC Assay (Label Claim Accuracy): We utilize advanced High-Performance Liquid Chromatography to simultaneously verify the exact concentrations of Levosalbutamol, Ambroxol, and Guaiphenesin, ensuring they strictly meet IP specifications (95–105% of label claim).
• Viscosity & Rheological Profiling: We measure the flow resistance to confirm the syrup maintains its soothing demulcent properties without becoming too thick to pour accurately.
• pH Mapping of Vehicle: Tested to confirm the liquid remains within the pre-validated pH range that prevents hydrolytic degradation of the APIs.
• Microbial Limit Test (MLT): IP-mandated microbiological testing confirming the complete absence of specified pathogens (such as E. coli and Salmonella) and verifying total aerobic microbial limits.
• Certificate of Analysis (COA): A comprehensive, parameter-complete COA is issued alongside every B2B batch dispatch, ensuring your brand is perpetually audit-ready for state FDA inspections and hospital formulary reviews.

While this formulation is safer than traditional racemic salbutamol combinations, healthcare professionals must be aware of its pharmacological profile:

• Adverse Effects: Generally mild. May include fine tremors of the skeletal muscle (particularly the hands), mild tachycardia, palpitations, headache, or mild gastrointestinal disturbances (nausea due to Guaiphenesin).
• Contraindications: Contraindicated in patients with a known hypersensitivity to any of the components.
• Precautions: Use with extreme caution in patients with cardiovascular disorders (especially ischemic heart disease or arrhythmias), hyperthyroidism, diabetes mellitus, and those with a history of peptic ulcers (as mucolytics may disrupt the gastric mucosal barrier).
• Drug Interactions: Co-administration with other sympathomimetic agents should be avoided. Caution is advised when used alongside MAO inhibitors, tricyclic antidepressants, or non-selective beta-blockers.
• Healthcare professionals should refer to the complete prescribing information for full safety data before dispensing.

For high-volume contract manufacturing agreements, third-party supply arrangements, or to request complete technical dossiers and pricing for Levosalbutamol, Ambroxol & Guaifenesin Syrup, please use the B2B enquiry form below.